Concepedia

Hans‐Georg Lerchen

HL

17

Publications

575

Citations

15

H-Index

1987

Active since

Affiliations

Bayer (Germany)(Current)

Bayer (France)

University of Wuppertal

Hans‐Georg Lerchen is an author at Bayer (Germany) specializing in medicine, pharmacology, and biomolecular engineering.

ORCID

Top concepts

Publications per year

1987–2023

17

Publications

17

Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

Anette Sommer, Charlotte Kopitz, Christoph A. Schatz et al. · Cancer Research · 2016 · 73 citations

, , +16

Design and Optimization of 20-O-Linked Camptothecin Glycoconjugates as Anticancer Agents

Hans‐Georg Lerchen, Joerg Baumgarten, Karsten von dem Bruch et al. · Journal of Medicinal Chemistry · 2001 · 70 citations

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A<sub>1</sub> Receptor Agonist for the Chronic Treatment of Heart Diseases

Daniel Meibom, Barbara Albrecht‐Küpper, Nicole Diedrichs et al. · ChemMedChem · 2017 · 54 citations

A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy

Paul Hoppenz, Sylvia Els‐Heindl, Martin Kellert et al. · The Journal of Organic Chemistry · 2019 · 51 citations

Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer

Jörg Willuda, Lars Lindén, Hans‐Georg Lerchen et al. · Molecular Cancer Therapeutics · 2017 · 45 citations

Rows per page

1–5 of 17